Novartis Gets CDSCO Panel Nod To Study Antiparasitic drug LXE408
New Delhi: Drug major Novartis has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the clinical study of the antiparasitic drug LXE408.
The firm presented phase 1 clinical study protocol no.: CLXE408A12105 amendment version no. 1 dated 31-January- 2025.
LXE408 is a first-in-class parasite-selective inhibitor of the kinetoplastid proteasome with potent and uniform anti-parasitic activity against all kinetoplastid parasites, including Leishmania species causing visceral leishmaniasis (L. donovani and L. infantum), as well as parasites causing Chagas disease (T. cruzi) and human African trypanosomiasis (T. brucei).
At the recent SEC meeting for antimicrobials and antivirals held on 13th and 14th February 2025, the expert panel reviewed the phase 1 clinical study protocol no.: CLXE408A12105amendment version no. 1 dated 31-January- 2025.
After detailed deliberation, the committee recommended the grant of permission to conduct the trial as presented by the firm.
Also Read: Alkem Laboratories Gets CDSCO Panel Nod To Study Semaglutide solution for injection
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.